Watertown, MA, United States of America

Xiao-Mai Zhou

USPTO Granted Patents = 3 


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Location History:

  • Watertown, MA (US) (2015)
  • Danbury, CT (US) (2013 - 2018)

Company Filing History:


Years Active: 2013-2018

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Inventor Xiao-Mai Zhou

Introduction

Xiao-Mai Zhou is a notable inventor based in Watertown, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 3 patents to his name, Zhou's work focuses on innovative solutions for cancer treatment.

Latest Patents

Zhou's latest patents include the development of EPHA2 receptor antagonist antibodies. These antagonistic antibodies specifically bind to and inhibit Class A Eph receptors. The patents also cover cytotoxic conjugates, pharmaceutical compositions, and kits that incorporate these antibodies. Furthermore, methods of use for antibodies that specifically bind to the EphA2 receptor are detailed in his patents. These antibodies can be utilized in treating tumors that express elevated levels of A class Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, and pancreatic cancer. The patents also describe derivatized antibodies for diagnosis and imaging of such tumors.

Career Highlights

Xiao-Mai Zhou is currently employed at Sanofi, where he continues to advance his research in therapeutic antibodies. His work has the potential to significantly impact cancer treatment and improve patient outcomes.

Collaborations

Zhou collaborates with talented professionals in his field, including Veronique Blanc and Claudia Fromond. Their combined expertise contributes to the innovative research and development efforts at Sanofi.

Conclusion

Xiao-Mai Zhou's contributions to the field of biotechnology through his patents and research at Sanofi highlight his commitment to advancing cancer treatment. His innovative work with EPHA2 receptor antagonist antibodies represents a significant step forward in therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…